Are You Taking Any of These 5 Common Medications Linked to Lower Dementia Risk?

Are You Taking Any of These 5 Common Medications Linked to Lower Dementia Risk?

Are You Taking Any of These 5 Common Medications Linked to Lower Dementia Risk?
Adobe Stock (3)

Medications for conditions like high blood pressure, diabetes, or high cholesterol could have more benefits than just treating the diseases they're prescribed for.

Growing evidence suggests that some medications commonly prescribed for conditions linked to dementia risk may also be associated with better long-term brain health.

 But researchers can’t yet say these medications prevent dementia — and experts caution that none of them should be taken solely to prevent the condition, which is broadly described as the loss of cognitive function.

“To say that a medication prevents dementia, we ideally need randomized controlled trials, where people without dementia are randomly assigned to treatment or control and followed over time,” explains Mozhu Ding, PhD, a geriatric epidemiologist and an assistant professor at the Institute of Environmental Medicine at Karolinska Institutet in Stockholm, who has researched medications and dementia. “Even then, dementia is difficult to study because it develops slowly, so trials need long follow-up and enough dementia cases to detect an effect.”

Certainly, some dementia risk factors — like age and genetics — can’t be changed. But treating underlying conditions that can damage the brain over time — including taking medications when necessary — can support long-term brain health in combination with brain-healthy habits like regular exercise, quality sleep, and eating a nutritious diet.

1. Blood Pressure Medications

Medications for treating high blood pressure (hypertension) — one of the biggest controllable risk factors for dementia — could help protect the brain’s blood vessels, reducing damage that can contribute to vascular (stroke-related) dementia and Alzheimer’s disease.

Some research suggests that certain blood pressure medications may be associated with a lower dementia risk than others. For instance, an Australian study analyzed outcomes of more than 51,500 adults with hypertension who were taking angiotensin receptor blockers (ARBs) or ACE (angiotensin-converting enzyme) inhibitors. The study found that those taking ARBs had a 28 percent lower risk of developing dementia than those taking ACE inhibitors. This suggests ARBs may have a potential role in preventing dementia, but the study was observational, so randomized controlled trials are needed to confirm these findings.

Experts say these results build on earlier evidence showing that strict blood pressure control to a target below 120 millimeters of mercury (mmHg) for systolic pressure (the top number) can reduce the risk of mild cognitive impairment, compared with standard blood pressure treatment with a target below 140 mmHg.

“The evidence for antihypertensives [reducing dementia risk] is among the strongest,” says Serena Jingchuan Guo, MD, PhD, an associate professor at Purdue University in West Lafayette, Indiana, who has researched the relationship between medications and dementia. “But this applies mainly to people with hypertension — not to people with normal blood pressure taking medication solely for brain protection.”

2. GLP-1 Medications

Originally developed to treat type 2 diabetes and now widely prescribed for obesity, glucagon-like peptide-1 (GLP-1) receptor agonists improve blood sugar control and reduce inflammation, enhancing blood vessel function and supporting overall metabolic health.

 Researchers are investigating whether those same effects of GLP-1s such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) could also benefit the brain.

Animal studies suggest that these drugs may reduce inflammation and other processes involved in brain cell damage, while other researchers are investigating whether their effects on blood sugar and heart health could reduce dementia risk.

“I think people are excited about these drugs based on animal studies and observational research,” says Amalia Peterson, MD, a behavioral neurologist and an assistant professor of neurology at Vanderbilt University Medical Center in Nashville, Tennessee. “There is promise for GLP-1 medications, but we’re still learning about them, so we do have to be cautious, because correlation is not the same as causation.”

Some recent human observational research has been encouraging, including one Danish study of older adults with type 2 diabetes finding that those taking GLP-1s had a lower risk of developing major cognitive impairment over three years versus those who were taking another type of diabetes medication.

But clinical trials haven’t yet shown that GLP-1 medications improve cognition in people who already have cognitive decline. One recent meta-analysis of randomized controlled trials found that liraglutide and exenatide did not significantly improve cognitive outcomes compared with placebo in people without diabetes who had mild cognitive impairment or Alzheimer’s disease.

“GLP-1s remain promising for brain health, especially through cardiometabolic pathways, but they are not established dementia-prevention or Alzheimer’s-treatment drugs,” Dr. Guo says.

3. Statins

Because they lower high cholesterol and reduce key dementia risk factors like blood vessel or vascular disease and stroke, researchers have explored whether statins might also help preserve cognitive health.

“So far, cardiovascular drugs overall are the most studied in relation to dementia risk, including medications used to treat high blood pressure, atrial fibrillation, and high lipid levels,” says Dr. Ding. The reason these have gained such attention is because the research has established strong connections between cardiovascular diseases and dementia, she explains.

One systematic review and meta-analysis of 55 observational studies involving more than seven million people found that statin use is associated with a 14 percent lower risk of dementia and an 18 percent lower risk of Alzheimer’s disease compared with not taking statins for cholesterol. Researchers say this may be linked with the drug’s ability to protect blood vessels in the brain and fight brain inflammation.

But the findings aren’t consistent. Previous reports show some statin users experience short-term cognitive decline — such as memory loss, forgetfulness, and confusion — so experts can’t say definitively whether statins have a positive impact on dementia risk.

“The evidence is not as strong as it is for blood pressure medications,” says Natasha Bhuyan, MD, a family physician who specializes in reproductive health at One Medical in Scottsdale, Arizona. “Some studies show that statins might have a moderate impact on dementia risk, which could be due to reducing inflammation and stabilizing blood vessels. But they shouldn’t be taken by people who don’t need them.”

Experts emphasize that future clinical trials are needed to better understand statins’ long-term effects on cognition.

4. Routine Vaccines

Certain routine vaccinations may offer an unexpected benefit beyond protecting against infectious diseases: They may also help support long-term brain health, with research linking several vaccines with a lower risk of dementia.

The strongest evidence so far is for the shingles vaccine. A 2025 study found that adults who received the vaccine were about 20 percent less likely to develop dementia over the following seven years than similar adults who weren’t vaccinated.

Other routine vaccinations — including annual flu shots — may also be associated with a lower dementia risk. A systematic review and meta-analysis found that those who got the influenza vaccination had a 13 percent lower risk of dementia than those who didn't get the vaccine, though much of the evidence was observational and the studies differed considerably in their methods and findings, making it more difficult to draw firm conclusions about whether the vaccination itself lowered dementia risk.

Researchers are still working to understand the connection, but one theory is that vaccines may lower dementia risk by preventing infections that can trigger chronic inflammation and damage to the brain and blood vessels. “These are observational studies, so we can’t make a definitive conclusion, but [the shingles vaccine] has the most compelling and large-scale evidence,” Dr. Bhuyan says, noting that the shingles infection could damage brain cells and blood vessels. “So by preventing the infection, we are preventing the risk of dementia.”

Guo agrees that the findings are encouraging but should be interpreted cautiously, noting that vaccines should be taken according to public health recommendations, but not as proven dementia-prevention drugs.

5. SGLT2 Inhibitors

Researchers are also investigating whether SGLT2 inhibitors — medications used to treat type 2 diabetes, such as empagliflozin (Jardiance) and dapagliflozin (Farxiga) — may protect the brain by improving blood sugar control, reducing inflammation, and supporting heart health.

The evidence so far has been mixed. One recent review of available research found that SGLT2 inhibitor use in people with type 2 diabetes was consistently associated with a lower risk of dementia than in those not taking the medications.

 But a separate meta-analysis of 26 randomized clinical trials did not find a significant reduction in dementia risk with SGLT2s.

Guo says for people with type 2 diabetes, the findings that diabetes medications may contribute to lower dementia risk are promising, but not definitive. “However, randomized trial evidence remains limited, and we cannot assume the effect applies to people without diabetes,” she says.

Bhuyan agrees. “The evidence is not as strong here,” she says. “These medications likely have an impact on both blood sugar control and reducing the risk of heart failure, but they do not help people without diabetes.”

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Real-World Data Suggest Two Antidiabetic Drug Classes May Curb Alzheimer’s Risk. Cleveland Clinic. October 15, 2025.
  2. What Is Dementia? Symptoms, Types, and Diagnosis. National Institute on Aging. December 8, 2022.
  3. Reducing Risk for Dementia. Centers for Disease Control and Prevention. August 27, 2024.
  4. Omura JD et al. Modifiable Risk Factors for Alzheimer Disease and Related Dementias Among Adults Aged ≥45 Years — United States, 2019. Centers for Disease Control and Prevention. May 20, 2022.
  5. Belachew EA et al. Long-Term Risk of Dementia With Angiotensin Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Patients: A 15-Year Follow-Up Using the 45 and Up Study. GeroScience. February 27, 2026.
  6. Jiang C et al. Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial. Hypertension. January 23, 2023.
  7. GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
  8. Seminer A et al. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta Analysis. JAMA Neurology. April 7, 2025.
  9. Battini V et al. Comparing Major and Mild Cognitive Impairment Risks in Older Type-2 Diabetic Patients: A Danish Register-Based Study on Dipeptidyl Peptidase-4 Inhibitors vs. Glucagon-Like Peptide-1 Analogues. Journal of Neurology. March 22, 2024.
  10. O’Mara A et al. The Effect of GLP-1 Receptor Agonists on Cognition in Nondiabetic Patients With Mild Cognitive Impairment or Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Trials. Neurological Sciences. January 12, 2026.
  11. Do Statins Increase Dementia Risk? Cleveland Clinic. May 13, 2026.
  12. Westphal Filho FL et al. Statin Use and Dementia Risk: A Systematic Review and Updated Meta-Analysis. Alzheimer’s & Dementia. January 16, 2025.
  13. Bilodeau K. Do Statins Increase the Risk of Dementia? Harvard Health Publishing. October 1, 2021.
  14. Shmerling RH. Can a Routine Vaccine Prevent Dementia? Harvard Health Publishing. April 29, 2025.
  15. Eyting M et al. A Natural Experiment on the Effect of Herpes Zoster Vaccination on Dementia. Nature. April 2, 2025.
  16. Maggi S et al. Association Between Vaccinations and Risk of Dementia: A Systematic Review and Meta-Analysis. Age & Ageing. November 21, 2025.
  17. Pawlos A et al. Neuroprotective Effect of SGLT2 Inhibitors. Molecules. November 28, 2021.
  18. Hung C-H et al. New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia. Neurology International. December 5, 2024.
Jessica-Baity-bio

Jessica Baity, MD

Medical Reviewer

Jessica Baity, MD, is a board-certified neurologist practicing in southern Louisiana. She cares for a variety of patients in all fields of neurology, including epilepsy, headache, ...

Cristina Mutchler

Cristina Mutchler

Author

Cristina Mutchler is an award-winning journalist with more than a decade of experience covering health and wellness content for national outlets. She previously worked at CNN, News...